Sera Prognostics CEO and leadership

Gregory Critchfield joined Sera Prognostics as Chairman & CEO in 2011.Until his retirement in March 2010, Dr. Gregory Critchfield was President and Board Member of Myriad Genetic Laboratories, Inc., the diagnostic subsidiary of Myriad Genetics, Inc., where he was responsible for building its scientific, medical, and commercial capabilities and launching seven novel molecular diagnostic products across a variety of technology platforms. Prior to Myriad, he served as Chief Medical and Science Officer with responsibility for science, medicine, and innovation at Corning Clinical Laboratories, which became Quest Diagnostics, Inc. He chaired the Governor's State Advisory Council on Science and Technology for the state of Utah in 2007. He has and continues to serve as an independent director in industry associations and various life science companies. Earlier in his career, Dr. Critchfield worked as a practicing clinical pathologist with Intermountain Healthcare for nine years and served on the faculty of the medical schools of University of Minnesota, Wayne State University and Duke University. He served as a reviewer and study section chair for the NIH for over 15 years in biomedical computing programs for SBIR, STTR and R01 programs. His research has focused on building quantitative models in many areas of laboratory medicine including anticoagulation control, method standardization, mass spectrometric identification of drugs, predictive value modeling, quantitative health policy analysis and clinical genetics. Dr. Critchfield received a Bachelor's Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, an M.D. degree from the University of Utah in 1980, and a master's degree in Biophysical Sciences at the University of Minnesota in 1985. There he also completed fellowships in Clinical Chemistry and in Health Information Sciences sponsored by the National Library of Medicine and is a diplomat of the American Board of Pathology.

Jay Boniface is a Chief Scientific Officer at Sera Prognostics and is based in Salt Lake City, Utah. He has worked as Director:Program/Scientist at Prolexys Pharmaceuticals Inc, Director:Program/Scientist at EOS Biotechnology, and Director:Program/Scientist at MYRIAD GENETICS INC. Jay studied at University at Albany.

Jay Moyes has over 30 years of management and leadership experience. Throughout his career, he has worked with numerous industry-leading companies through their transformation from emerging growth to established, publicly-traded companies.

As an innovative and visionary healthcare business leader who drives paradigm changes, I have a proven executive management track record and 20 years of experience driving value creation and raising capital in the biotech and diagnostics sectors. Throughout my career, I have achieved an impressive list of firsts in bringing novel products to market. I am a forward thinker on commercialization strategies, operational infrastructure, and strategic partnerships that has contributed to the success of numerous business ventures. I am sought out for insight on go-to-market approaches that drive revenue and market ownership. Currently, I am the Chief Commercial Officer of Sera Prognostics Inc., a leader in high-value women’s health diagnostics. I am focused on its breakthrough diagnostics product where I architected and lead the commercialization strategy and execution, implementing the building blocks for widespread payer coverage and market adoption while supporting fundraising activities.Previously, as President and then CEO and member of the Board of Directors at Abcodia Ltd, a clinical-stage company engaged in using human serum-based biomarkers to develop validated tests for the early detection of cancer, I set up the U.S. subsidiary and oversaw the subsequent launch of global commercial operations. I directed a series of operational reengineering, regulatory compliance, organization restructuring, strategic planning, and other activities.Prior to Abcodia, I was Vice President & General Manager at ThermoFisher Scientific, a multinational biotechnology product development company where I turned around an under-performing business that was suffering market share losses and revenue growth decline. Among my accomplishments was the startup, build & scale of the ViaCord division.I am currently on the Board of Savran Technologies, a private healthcare company focused on enabling the next generation of non-invasive diagnostics. Previously I served on the Board of Abcodia, a women’s health diagnostics company, in both non-executive & executive director roles. I also served as the PerkinElmer representative to the Boston Chapter of the March of Dimes Board. 🛫 I am available to travel and/or relocate.𝗔𝗥𝗘𝗔𝗦 𝗢𝗙 𝗘𝗫𝗣𝗘𝗥𝗧𝗜𝗦𝗘🔹 LDT/FDA Regulatory Environment🔹 Commercialization🔹 Build and/or Scale Organizations🔹 Turnarounds🔹 Global Expansion🔹 Product Launch & Go-to-Market Strategies🔹 Stakeholder Engagement🔹 Culture Building 🔹 Scientific, Strategic & Business Acumen🔹 Inspirational Motivator🔹 Influencer 🔹 Talent Magnet

Robert G. Harrison, chief information officer, joined Myriad in 1996. He served as Myriad's Network Administrator from 1996 to 2000 and was named director of information systems and technology in 2000. Mr. Harrison was named vice president of information systems and technology in 2005, a position he held until January 2008 when he was named chief information officer. He began his career in IT working for several private companies and consulting firms where he held positions in technical support, sales and management roles. Mr. Harrison received a B.S. degree in Business Administration with a minor in Computer Science from the University of Utah in 1994.

Gregory Critchfield joined Sera Prognostics as Chairman & CEO in 2011.Until his retirement in March 2010, Dr. Gregory Critchfield was President and Board Member of Myriad Genetic Laboratories, Inc., the diagnostic subsidiary of Myriad Genetics, Inc., where he was responsible for building its scientific, medical, and commercial capabilities and launching seven novel molecular diagnostic products across a variety of technology platforms. Prior to Myriad, he served as Chief Medical and Science Officer with responsibility for science, medicine, and innovation at Corning Clinical Laboratories, which became Quest Diagnostics, Inc. He chaired the Governor's State Advisory Council on Science and Technology for the state of Utah in 2007. He has and continues to serve as an independent director in industry associations and various life science companies. Earlier in his career, Dr. Critchfield worked as a practicing clinical pathologist with Intermountain Healthcare for nine years and served on the faculty of the medical schools of University of Minnesota, Wayne State University and Duke University. He served as a reviewer and study section chair for the NIH for over 15 years in biomedical computing programs for SBIR, STTR and R01 programs. His research has focused on building quantitative models in many areas of laboratory medicine including anticoagulation control, method standardization, mass spectrometric identification of drugs, predictive value modeling, quantitative health policy analysis and clinical genetics. Dr. Critchfield received a Bachelor's Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, an M.D. degree from the University of Utah in 1980, and a master's degree in Biophysical Sciences at the University of Minnesota in 1985. There he also completed fellowships in Clinical Chemistry and in Health Information Sciences sponsored by the National Library of Medicine and is a diplomat of the American Board of Pathology.

Dr. Fisher is a former partner of InterWest Partners, LLC, and served on Sera’s Board of Directors since the company’s Series A funding in November 2011. He joined Sera as its business and strategy development executive in January 2015 and continues to serve as an Executive-in-Residence at InterWest Partners. Dr. Fisher has focused on biopharmaceutical, diagnostic and medical device investments throughout his career, working in venture capital, consulting and pharmaceutical industries. He received his M.D. and M.B.A. from the School of Medicine and the Wharton School, respectively, at the University of Pennsylvania.